Crossmark

Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States

Crossref DOI link: https://doi.org/10.1007/s10461-017-2017-x

Published Online: 2017-12-30

Published Print: 2018-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kerrigan, D.

Mantsios, A.

Grant, R.

Markowitz, M.

Defechereux, P.

La Mar, M.

Beckham, S. Wilson

Hammond, P.

Margolis, D.

Murray, M.
Funding

Funding for this research was provided by:

ViiV Healthcare
License Information

Text and Data Mining valid from 2017-12-30

Version of Record valid from 2017-12-30
More Information

Article History

First Online: 30 December 2017

Compliance with Ethical Standards

:

: Deanna Kerrigan received support via a GSK contract. Andrea Mantsios received support via a GSK contract. Robert Grant was an investigator on trials supported in part by ViiV/GSK. Martin Markowitz was an investigator on trials supported in part by ViiV/GSK. Patricia Defechereux was staff on trials supported in part by ViiV/GSK. Melissa La Mar was staff on trials supported in part by ViiV/GSK. S. Wilson Beckham received support via a GSK contract. Paige Hammond received support via a GSK contract. David Margolis is an employee of ViiV Healthcare. Miranda Murray is an employee of ViiV Healthcare.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.

Document is current

Any future updates will be listed below